Literature DB >> 15774434

Population based mortality and quality of death certification in progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome).

U Nath1, R Thomson, R Wood, Y Ben-Shlomo, A Lees, C Rooney, D Burn.   

Abstract

OBJECTIVE: To estimate the mortality of progressive supranuclear palsy (PSP) and to assess the quality of death certification in patients with PSP who died in England and Wales.
METHODS: An analysis was conducted of ICD-9 (International Classification of Diseases, version 9) coded deaths obtained through the Office of National Statistics over an eight year period.
RESULTS: The crude annual mortality rate was 1.77 (95% confidence interval, 1.64 to 1.90) cases per million, using the mid-1996 population estimate for England and Wales. Annual mortality increased over time, possibly as a result of increased incidence or increased awareness of the disorder. Forty nine death certificates from deceased patients previously diagnosed clinically showed that the commonest proximate cause of death was pneumonia, occurring in 45% of cases (22/49). The underlying cause of death was cited as pneumonia in 14% of cases (7/49). PSP was mentioned in only 65% of death certificates (32/49). Eight of the 49 cases (16%) underwent necropsy and results were available for five of these cases. PSP was confirmed pathologically in four; the remaining case was diagnosed as Parkinson's disease.
CONCLUSIONS: Further research is needed to establish the reasons for the observed increase in mortality. Determining the population mortality rate for PSP using the ICD-9 coding system is problematic but is likely to improve following the introduction of ICD-10 updated codes and coding rules.

Entities:  

Mesh:

Year:  2005        PMID: 15774434      PMCID: PMC1739606          DOI: 10.1136/jnnp.2004.039370

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  7 in total

1.  PROGRESSIVE SUPRANUCLEAR PALSY. A HETEROGENEOUS DEGENERATION INVOLVING THE BRAIN STEM, BASAL GANGLIA AND CEREBELLUM WITH VERTICAL GAZE AND PSEUDOBULBAR PALSY, NUCHAL DYSTONIA AND DEMENTIA.

Authors:  J C STEELE; J C RICHARDSON; J OLSZEWSKI
Journal:  Arch Neurol       Date:  1964-04

2.  Mortality trends by cause of death in England and Wales 1980-94: the impact of introducing automated cause coding and related changes in 1993.

Authors:  C Rooney; T Devis
Journal:  Popul Trends       Date:  1996

3.  The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK.

Authors:  U Nath; Y Ben-Shlomo; R G Thomson; H R Morris; N W Wood; A J Lees; D J Burn
Journal:  Brain       Date:  2001-07       Impact factor: 13.501

Review 4.  Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop.

Authors:  I Litvan; Y Agid; D Calne; G Campbell; B Dubois; R C Duvoisin; C G Goetz; L I Golbe; J Grafman; J H Growdon; M Hallett; J Jankovic; N P Quinn; E Tolosa; D S Zee
Journal:  Neurology       Date:  1996-07       Impact factor: 9.910

5.  The epidemiology of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome).

Authors: 
Journal:  Parkinsonism Relat Disord       Date:  2000-07-01       Impact factor: 4.891

6.  Progressive supranuclear palsy 1979: an overview.

Authors:  A Brusa; G L Mancardi; O Bugiani
Journal:  Ital J Neurol Sci       Date:  1980-10

7.  The clinical features and natural history of the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy).

Authors:  E R Maher; A J Lees
Journal:  Neurology       Date:  1986-07       Impact factor: 9.910

  7 in total
  14 in total

1.  Multiple system atrophy: prognostic indicators of survival.

Authors:  Juan J Figueroa; Wolfgang Singer; Ajay Parsaik; Eduardo E Benarroch; J Eric Ahlskog; Robert D Fealey; Joseph E Parisi; Paola Sandroni; Jay Mandrekar; Valeria Iodice; Phillip A Low; James H Bower
Journal:  Mov Disord       Date:  2014-06-07       Impact factor: 10.338

2.  SARS-CoV-2 Brain Regional Detection, Histopathology, Gene Expression, and Immunomodulatory Changes in Decedents with COVID-19.

Authors:  Geidy E Serrano; Jessica E Walker; Cécilia Tremblay; Ignazio S Piras; Matthew J Huentelman; Christine M Belden; Danielle Goldfarb; David Shprecher; Alireza Atri; Charles H Adler; Holly A Shill; Erika Driver-Dunckley; Shyamal H Mehta; Richard Caselli; Bryan K Woodruff; Chadwick F Haarer; Thomas Ruhlen; Maria Torres; Steve Nguyen; Dasan Schmitt; Steven Z Rapscak; Christian Bime; Joseph L Peters; Ellie Alevritis; Richard A Arce; Michael J Glass; Daisy Vargas; Lucia I Sue; Anthony J Intorcia; Courtney M Nelson; Javon Oliver; Aryck Russell; Katsuko E Suszczewicz; Claryssa I Borja; Madison P Cline; Spencer J Hemmingsen; Sanaria Qiji; Holly M Hobgood; Joseph P Mizgerd; Malaya K Sahoo; Haiyu Zhang; Daniel Solis; Thomas J Montine; Gerald J Berry; Eric M Reiman; Katharina Röltgen; Scott D Boyd; Benjamin A Pinsky; James L Zehnder; Pierre Talbot; Marc Desforges; Michael DeTure; Dennis W Dickson; Thomas G Beach
Journal:  J Neuropathol Exp Neurol       Date:  2022-08-16       Impact factor: 3.148

3.  Accuracy of death certificates for recording parkinsonian syndromes and associated dementia.

Authors:  Hanxu Shi; Carl Counsell
Journal:  J Neurol       Date:  2020-07-31       Impact factor: 4.849

4.  Extremely low-frequency magnetic field exposure, electrical shocks and risk of Parkinson's disease.

Authors:  Marianne van der Mark; Roel Vermeulen; Peter C G Nijssen; Wim M Mulleners; Antonetta M G Sas; Teus van Laar; Hans Kromhout; Anke Huss
Journal:  Int Arch Occup Environ Health       Date:  2014-06-18       Impact factor: 3.015

5.  Is Parkinson's disease-related mortality declining?

Authors:  E Haberfeld; E D Louis
Journal:  Eur J Neurol       Date:  2009-06-30       Impact factor: 6.089

Review 6.  Prognostic predictors relevant to end-of-life palliative care in Parkinson's disease and related disorders: a systematic review.

Authors:  Umer Akbar; Robert Brett McQueen; Julienne Bemski; Julie Carter; Elizabeth R Goy; Jean Kutner; Miriam J Johnson; Janis M Miyasaki; Benzi Kluger
Journal:  J Neurol Neurosurg Psychiatry       Date:  2021-03-31       Impact factor: 10.154

7.  Gray and White Matter Correlates of Dysphagia in Progressive Supranuclear Palsy.

Authors:  Heather M Clark; Nirubol Tosakulwong; Stephen D Weigand; Farwa Ali; Hugo Botha; Nha Trang Thu Pham; Christopher G Schwarz; Robert I Reid; Matthew L Senjem; Clifford R Jack; Val J Lowe; J Eric Ahlskog; Keith A Josephs; Jennifer L Whitwell
Journal:  Mov Disord       Date:  2021-08-23       Impact factor: 10.338

8.  Impact of Aspiration Pneumonia on the Clinical Course of Progressive Supranuclear Palsy: A Retrospective Cohort Study.

Authors:  Satoshi Tomita; Tomoko Oeda; Atsushi Umemura; Masayuki Kohsaka; Kwiyoung Park; Kenji Yamamoto; Hiroshi Sugiyama; Chiaki Mori; Kimiko Inoue; Harutoshi Fujimura; Hideyuki Sawada
Journal:  PLoS One       Date:  2015-08-13       Impact factor: 3.240

9.  Sepsis-associated mortality in England: an analysis of multiple cause of death data from 2001 to 2010.

Authors:  Duncan McPherson; Clare Griffiths; Matthew Williams; Allan Baker; Ed Klodawski; Bobbie Jacobson; Liam Donaldson
Journal:  BMJ Open       Date:  2013-08-02       Impact factor: 2.692

10.  A case of spinal anesthesia in a patient with progressive supranuclear palsy.

Authors:  Momoka Tonan; Moritoki Egi; Nana Furushima; Satoshi Mizobuchi
Journal:  JA Clin Rep       Date:  2018-01-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.